$3.5MSeed, 23 April 2026
Seed takes FRS-101 through antibody engineering and in vivo proof-of-concept studies.
- Amount
- $3.5M
- Stage
- Seed
- Announced
- 23 April 2026
- Lead
- Forty51 Ventures
- Use of funds
- Seed takes FRS-101 through antibody engineering and in vivo proof-of-concept studies.
- Checked
- Announced by the company
- Sources
- Ferrosa Therapeutics raises $3.5M seed for anemia antibody program digital-release.wgnradio.com
Ferrosa Therapeutics raises $3.5M seed for anemia antibody program pulse2.com